According to a report “Tuberculosis (TB) Drugs/Therapeutics Market Size, Share & Trends Analysis Report by Disease Type (Active TB, Latent TB), By Therapy (First-Line, Second-Line), By Region, Competitive Landscape, And Segment Forecasts, 2018 - 2025” published by Grand View Research, Inc, The global Tuberculosis Drugs/Therapeutics (TB) Market size is expected to reach USD 1.38 billion by 2025, according to a new report by Grand View Research, Inc., registering a CAGR of 5.2% during the forecast period. Rising prevalence of Multidrug Resistant (MDR) tuberculosis and HIV-tuberculosis co-infection is likely to drive the market during the forecast period. According to WHO, in 2017, the annual incidence of tuberculosis (TB) in India was 2.8 million cases, with an estimated 147,000 multi-drug resistant cases. India has the second highest estimation of HIV-TB co-infection cases per year, i.e., 87,000.
Key Takeaways from the report:
- Collaborative efforts among international organizations and pharmaceutical players are spurring drug development and treatment access, which is expected to propel the growth of the tuberculosis drugs market
- In March 2015, a collaboration between the United States Agency for International Development (USAID) and the Janssen Global Services, LLC was undertaken to provide the drug bedaquiline free of cost to eligible MDR-tuberculosis patients
- Based on disease type, the active tuberculosis drugs segment accounted for the largest share of 87.3% in 2016. If undiagnosed, latent tuberculosis has the potential to transform to the active form, which has led countries in Europe and North America to focus on early diagnosis and preventive measures
- Based on therapy type, second-line therapy drugs led the market with a share of 60.4% in 2016. Rising incidence and higher treatment cost structure of MDR tuberculosis, coupled with increasing treatment access, is spurring market growth
- Regionally, Asia Pacific held a major market share and is expected to retain its dominance during the forecast period due to high disease incidence and gradual improvement in patient medication adherence rates
- Europe is likely to witness significant growth over the next decade due to high MDR-TB burden, along with improved focus on LTBI treatment drugs
- Some of the key players in the tuberculosis drugs market are Johnson & Johnson (J&J) Services, Lupin, Pfizer, Novartis AG, Macleods Pharmaceuticals Limited, and Otsuka Pharmaceutical Co., Ltd.
Browse More Reports in Pharmaceuticals Industry:
Peptide Therapeutics Market - Increasing prevalence of cancer and metabolic disorders such as osteoporosis, obesity, & diabetes are the key factors contributing toward the adoption of peptide therapeutics over the forecast period.
Aptamers Market - The market is expected to grow due to advancements in technologies, i.e., Systemic Evolution of Ligands by Exponential Enrichment (SELEX) process.
The TB drugs market is expected to witness high growth in the coming years due to development of shorter-regimen drug treatments and availability of private and public funding. The Nix-TB trial currently being conducted by TB Alliance in conjunction with Janssen Pharmaceuticals involves a combination of drugs, pretomanid, linezolid, and bedaquiline, which promises a cure for Extensively Drug Resistant (XDR) form of the disease within 6-9 months.
Apart from competitive dynamics, license agreements among players are providing opportunities for emerging drug manufacturers to grow in this space. In September 2015, Dishman Group received a license agreement from Janssen Pharmaceutica NV, subsidiary of Johnson & Johnson Services, LLC to produce the active pharmaceutical ingredient (API) for the drug Sirturo (bedaquiline), intended for MDR TB treatment. Dishman, apart from being an API supplier for Janssen’s novel drug, is now listed as a licensed API manufacturer with the EMA, USFDA, and several Asian regulatory authorities.
Grand View Research has segmented the global tuberculosis drugs market based on disease type, therapy, and region:
Tuberculosis Drugs Disease Type (Revenue, USD Million, 2014 - 2025)
- Active TB
- Latent TB
Tuberculosis Drugs Therapy (Revenue, USD Million, 2014 - 2025)
- First-Line Therapy
- Second-Line Therapy
Tuberculosis Drugs Regional Outlook (Revenue, USD Million, 2014 - 2025)
- North America
- U.S.
- Canada
- Europe
- U.K.
- France
- Germany
- Asia Pacific
- China
- India
- Philippines
- Latin America
- Brazil
- Mexico
- Africa
- South Africa
- Nigeria
Explore the BI enabled intuitive market research database, Navigate with Grand View Compass, by Grand View Research, Inc.
About Grand View Research
Grand View Research provides syndicated as well as customized research reports and consulting services on 46 industries across 25 major countries worldwide. This U.S.-based market research and consulting company is registered in California and headquartered in San Francisco. Comprising over 425 analysts and consultants, the company adds 1200+ market research reports to its extensive database each year. Supported by an interactive market intelligence platform, the team at Grand View Research guides Fortune 500 companies and prominent academic institutes in comprehending the global and regional business environment and carefully identifying future opportunities.
For more information: www.grandviewresearch.com
Media Contact
Company Name: Grand View Research, Inc.
Contact Person: Sherry James, Corporate Sales Specialist - U.S.A.
Email:Send Email
Phone: 1-415-349-0058, Toll Free: 1-888-202-9519
Address:201, Spear Street, 1100
City: San Francisco
State: California
Country: United States
Website: www.grandviewresearch.com/industry-analysis/tuberculosis-tb-drugs-therapeutics-market
